阿斯利康AstraZeneca plc (AZN) 2012年年度报告「LSE」.pdf

1、Registered office andcorporate headquartersAstraZeneca PLC2 Kingdom StreetLondon W2 6BDUKTel:+44(0)20 7604 8000Fax:+44(0)20 7604 8151Investor UK:as aboveUSInvestor RelationsAstraZeneca Pharmaceuticals LP1800 Concord PikePO Box 15437WilmingtonDE 19850-5437USTel:+1(302)886 3000Fax:+1(302)886 2972Regis

2、trarEquiniti Limited Aspect HouseSpencer RoadLancingWest Sussex BN99 6DAUKTel:(freephone in the UK)0800 389 1580 Tel:(outside the UK)+44(0)121 415 7033Swedish Central Securities DepositoryEuroclear Sweden ABPO Box 191SE-101 23 StockholmSwedenTel:+46(0)8 402 9000US DepositaryJPMorgan Chase&CoPO Box 6

3、4504St PaulMN 55164-0504USTel:(toll free in the US)888 697 8018 Tel:(outside the US)+1(651)453 2128 This Annual Report is also available on our website, value through innovationAstraZeneca Annual Report and Form 20-F Information 2012AstraZeneca Annual Report and Form 20-F Information 2012+-AstraZene

4、caWelcome to the AstraZeneca Annual Report and Form 20-F Information 2012 (Annual Report).You will find this Annual Report on our website, compete as a global biopharmaceutical business delivering great medicines to patients through innovative science and excellence in development and commercialisat

5、ionPerformance2012 financial performance was defined by significant revenue decline associated with the loss of exclusivity for several productsCorporateGovernanceIn addition to the regular programme of meetings for the Board and its Committees 2012 was a busy year with new appointments,a record num

6、ber of business development deals and our strategic reviewFinancial StatementsMet or exceeded financial targets as a result of disciplined financial management and lower Reported tax rateAdditional InformationMore information about our business and about being an AstraZeneca shareholderInnovation is